Roth Capital reiterated their buy rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research report report published on Wednesday morning. They currently have a $520.00 price objective on the biopharmaceutical company’s stock.
Several other brokerages also recently commented on REGN. Robert W. Baird restated a neutral rating and issued a $448.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, September 23rd. Goldman Sachs Group Inc. restated a buy rating and issued a $521.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 27th. Vetr downgraded shares of Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $419.76 price target for the company. in a research report on Monday, July 11th. Sanford C. Bernstein restated a buy rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 30th. Finally, Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, October 4th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company. The company currently has an average rating of Hold and an average target price of $480.09.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 366.73 on Wednesday. The firm has a market cap of $38.37 billion, a price-to-earnings ratio of 57.21 and a beta of 1.31. Regeneron Pharmaceuticals has a 12-month low of $329.09 and a 12-month high of $592.59. The company’s 50 day moving average is $396.54 and its 200 day moving average is $392.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.65 by $0.17. The business earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The firm’s quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.89 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.40% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Putnam FL Investment Management Co. boosted its stake in Regeneron Pharmaceuticals by 0.4% in the third quarter. Putnam FL Investment Management Co. now owns 14,923 shares of the biopharmaceutical company’s stock valued at $5,999,000 after buying an additional 61 shares during the last quarter. CrestPoint Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $402,000. National Pension Service boosted its stake in Regeneron Pharmaceuticals by 8.9% in the third quarter. National Pension Service now owns 52,106 shares of the biopharmaceutical company’s stock valued at $20,948,000 after buying an additional 4,240 shares during the last quarter. Highland Capital Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $856,000. Finally, Nisa Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 10.8% in the third quarter. Nisa Investment Advisors LLC now owns 15,440 shares of the biopharmaceutical company’s stock valued at $6,207,000 after buying an additional 1,500 shares during the last quarter. Hedge funds and other institutional investors own 68.32% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.